• Home
  • About
  • Capbilities
  • R&D
  • Investors
  • News
  • Careers
中文
  • Home
  • About
  • Capbilities
  • R & D
  • Investors
  • News
  • Careers
Innovative Cytokine 8MW0511 Obtained Clinical Approval

Release time:Feb 12, 2018

On February 12, 2018, the innovative cytokine 8MW0511 was issued with the Phase II and III clinical trial approval by China Food and Drug Administration.

Hot News
  • Mabwell announces NMPA approval of 9MW3811 for IND
  • Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA
  • Mabwell's First Self-commercialized Drug Reached its National Logistics Ceremony
  • China’s First Nectin-4 Targeted ADC Drug 9MW2821 Clinical Progress Released
  • The World's Second Approved Biosimilars of Denosumab (MAILISHU)
  • Mabwell's Clinical Trial Application for 9MW3811 Accepted by NMPA
  • About Who we are Management Milestone Awards Partnership Contact
  • Capbilities R&D Manufacturing Commericalization
  • R&D Pipeline High-tech Platforms R&D Progress
  • Investors Stock Information IR Contact
  • News Press Release
  • Careers Value Awards & Welfare Campus Recruitment Social Recruitment

Official wechat

Copyright ©2022 Mabwell (Shanghai) Bioscience Co., Ltd. 沪 ICP 备 17041957 号 Shanghai public network security:31011502008788

Legal Statement| Privacy Policy|